Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7013887 | 0.92 | SIGMAR1 (0.60) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| SCHEMBL5718487 | 0.86 | OPRM1 (0.57) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| SCHEMBL4464056 | 0.86 | OPRM1 (0.57) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| SCHEMBL3817982 | 0.83 | OPRM1 (0.59) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| SCHEMBL1220330 | 0.83 | OPRM1 (0.59) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| SCHEMBL7498815 | 0.83 | CHRM4 (0.55) | CHRM4SIGMAR1OPRM1HTR2AHTR2C | |
| SCHEMBL7498825 | 0.83 | CHRM4 (0.55) | CHRM4SIGMAR1OPRM1HTR2AHTR2C | |
| SCHEMBL26618028 | 0.83 | SIGMAR1 (0.57) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| Hydrochloric Acid SCHEMBL4469376 | 0.82 | OPRM1 (0.57) | CHRM4LTA4HSIGMAR1OPRM1HTR2A | |
| Hydrochloric Acid SCHEMBL4469375 | 0.82 | OPRM1 (0.57) | CHRM4LTA4HSIGMAR1OPRM1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | CHRM4 4482/4885LTA4H 4242/4885SIGMAR1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.